Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Pharmacy
Literature
1.
2.
Ding N, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease–algorithm for practical management. Aliment Pharmacol Ther. 2016;43(1):30–51.CrossRefPubMed
3.
Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus EV Jr. Comparative efficacy of biologic therapy in biologic-naive patients with Crohn disease: a systematic review and network meta-analysis. Mayo Clinic Proc. 2014;89(12):1621–35.CrossRef
4.
Feuerstein J, Nguyen G, Kupfer S, Falck-Ytter Y, Singh S. American gastroenterological association institute clinical guidelines committee American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827–34.CrossRefPubMed
5.
Casteele NV, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108(6):962–71.CrossRef
6.
Papamichael K, Cheifetz AS, Deaconess B. Letter: infliximab concentrations during induction therapy - one size doesn’t fit all. Aliment Pharmacol Ther. 2018;47:1334–5.CrossRefPubMed
7.
8.
Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(1320–1329):e3.
9.
Candel Gil M, Cánovas, Gascón J, Gómez Espín R, Nicolás De Prado I, Rentero Redondo L, Urbieta Sanz E, et al. Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients. 2020;112:590–7.
10.
Ungar B, Levy I, Yavne Y, Yavzori M, Picard O, Fudim E, et al. Optimizing Anti-TNF-α Therapy: Serum levels of Infliximab and Adalimumab are associated With Mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol [Internet] 2016;14:550–557.e2. https://​doi.​org/​10.​1016/​j.​cgh.​2015.​10.​025.
11.
Cohen RZ, Schoen BT, Kugathasan S, Sauer CG. Management of anti-drug antibodies to biologic medications in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2019;69:551–6.CrossRefPubMed
Metadata
Title
Drug survival of infliximab and adalimumab in inflammatory bowel disease
Authors
Erfan Asadipour
Mona Kargar
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 6/2020
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01151-9

Other articles of this Issue 6/2020

International Journal of Clinical Pharmacy 6/2020 Go to the issue

Commentary

Marketing of healthcare services in Denmark: the concept of misleading advertising

Research Article

Information needs and patient perceptions of the quality of medication information available in hospitals: a mixed method study

Research Article

Opportunistic screening of cardiovascular disease risk factors in community pharmacies in Nigeria: a cross-sectional study

Commentary

Creating clinical pharmacy capacity in Namibia: a collaboration to establish a post-graduate pharmacy degree programme

Research Article

Understanding medication safety and Charcot-Marie-Tooth disease: a patient perspective

Research Article

Exploring pharmacists’ views on an in-pharmacy medication review program in Australia using a mixed-methods design

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits